{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:24:32Z","timestamp":1769858672736,"version":"3.49.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.lungcan.2017.10.009","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:35:02Z","timestamp":1509064502000},"page":"68-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report"],"prefix":"10.1016","volume":"114","author":[{"given":"Anna","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wallace","family":"Akerley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"November (11)","key":"10.1016\/j.lungcan.2017.10.009_bib0005","first-page":"1962","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li]","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"June (6)","key":"10.1016\/j.lungcan.2017.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"December (12)","key":"10.1016\/j.lungcan.2017.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol."},{"issue":"June","key":"10.1016\/j.lungcan.2017.10.009_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2017.02.022","article-title":"Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient","volume":"108","author":"Gion","year":"2017","journal-title":"Lung Cancer"},{"issue":"July (7)","key":"10.1016\/j.lungcan.2017.10.009_bib0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.10.009_bib0030","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"May (3)","key":"10.1016\/j.lungcan.2017.10.009_bib0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolong survival of patients with non-small cell lung cancer with leptomeningeal cacinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.10.009_bib0040","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"January (4)","key":"10.1016\/j.lungcan.2017.10.009_bib0045","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.18632\/oncotarget.6758","article-title":"High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutatn lung cancer cells","volume":"7","author":"Nanjo","year":"2016","journal-title":"Oncotarget"},{"issue":"September","key":"10.1016\/j.lungcan.2017.10.009_bib0050","article-title":"Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA [abstract]","volume":"8\u201312","author":"Ramalingam","year":"2017","journal-title":"Eur. Soc. Med. Oncol."},{"issue":"October (20)","key":"10.1016\/j.lungcan.2017.10.009_bib0055","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.10.009_bib0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9002","article-title":"Osimertinib activity in patients with leptomeningeal metastases from non-small cell lung cancer: updated results from BLOOM, a phase I study (absstract)","volume":"34","author":"Yang","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T15:39:44Z","timestamp":1603208384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217305482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"alternative-id":["S0169500217305482"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.009","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}